Skeletalis is developing next-generation therapeutics aimed at musculoskeletal disorders, with an initial focus on osteoporosis. Its lead small-molecule candidate employs a proprietary bone-targeting technology that delivers disease-modulating therapy directly to skeletal tissue, minimizing systemic exposure. By re-engineering drug engagement with bone targets, the company seeks to improve tolerability, extend therapeutic durability, and ultimately prevent fractures while preserving bone mineral density. The approach is designed to avoid the safety liabilities associated with current osteoporosis drugs. Skeletalis is led by founder and CEO Ben Swanson, DDS, PhD, working alongside Dr. Colin Greineder. The recently secured financing will fund advancement of the osteoporosis candidate through pre-clinical and early clinical development. No operating metrics such as revenue or user count have been disclosed.

Total raised

$8M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025